Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Eradivir
company
About
Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $256K
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2020
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19. The company was founded in 2020 and is headquartered in West Lafayette, Indiana.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$256K
Eradivir has raised a total of
$256K
in funding over 2 rounds. Their latest funding was raised on
Feb 5, 2021 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 5, 2021 | Grant | $256K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Eradivir is funded by 1 investors.
National Science Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
